FDA layoffs and priority review programme’s lapse disrupt rare disease pipeline
The expiration of the FDA’s paediatric priority review voucher programme is creating uncertainty for rare disease drug developers.
The expiration of the FDA’s paediatric priority review voucher programme is creating uncertainty for rare disease drug developers.
What's Your Reaction?
